Literature DB >> 20384481

A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties.

Ulrike Samulowitz1, Markus Weber, Risini Weeratna, Eugen Uhlmann, Bernhard Noll, Arthur M Krieg, Jörg Vollmer.   

Abstract

Unmethylated deoxycytidyl-deoxyguanosin dinucleotide (CpG)-containing oligodeoxynucleotides (ODNs) have been well characterized as agonists for Toll-like receptor 9. We here describe a new class of CpG ODNs, the so-called P-Class, which combines preferred properties of known CpG ODN classes. This P-Class contains two palindromic sequences, enabling it to form concatamers, multimeric units, where each molecule is bound via Watson-Crick basepairing to a second and a third palindrome. The type I interferon-inducing potency and efficacy of the double-palindromic P-Class ODN is substantially higher than that of previously described C-Class ODNs, and they stimulate superior cytokine production upon in vivo application. The multimeric structures of the P-Class can be resolved to monomers and dimers by formulation in low-salt buffer, retaining the strong and potent immune effects. Taken together, we have discovered a novel class of CpG ODNs, the P-Class, with promising superior activity for disease application.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384481     DOI: 10.1089/oli.2009.0210

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  28 in total

1.  Human gestation-associated tissues express functional cytosolic nucleic acid sensing pattern recognition receptors.

Authors:  A H Bryant; G E Menzies; L M Scott; S Spencer-Harty; L B Davies; R A Smith; R H Jones; C A Thornton
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

Review 2.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

Review 3.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

4.  Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.

Authors:  Kouji Kobiyama; Taiki Aoshi; Hirotaka Narita; Etsushi Kuroda; Masayuki Hayashi; Kohhei Tetsutani; Shohei Koyama; Shinichi Mochizuki; Kazuo Sakurai; Yuko Katakai; Yasuhiro Yasutomi; Shinobu Saijo; Yoichiro Iwakura; Shizuo Akira; Cevayir Coban; Ken J Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 5.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  Vaccine       Date:  2014-06-24       Impact factor: 3.641

6.  Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists.

Authors:  Wenjun Meng; Tomohiko Yamazaki; Yuuki Nishida; Nobutaka Hanagata
Journal:  BMC Biotechnol       Date:  2011-09-26       Impact factor: 2.563

Review 7.  Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.

Authors:  Nobutaka Hanagata
Journal:  Int J Nanomedicine       Date:  2012-04-27

8.  Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.

Authors:  Norbert Donhauser; Kathrin Pritschet; Martin Helm; Thomas Harrer; Philipp Schuster; Moritz Ries; Georg Bischof; Jörg Vollmer; Sigrun Smola; Barbara Schmidt
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families.

Authors:  Céline Robert-Tissot; Vera L Rüegger; Valentino Cattori; Marina L Meli; Barbara Riond; Peter F Moore; Monika Engels; Marco Franchini; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2012-08-20       Impact factor: 3.683

10.  Synergistic induction of interferon α through TLR-3 and TLR-9 agonists identifies CD21 as interferon α receptor for the B cell response.

Authors:  Dhohyung Kim; Stefan Niewiesk
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.